Aptima® SARS-CoV-2/Flu Assay

Fully automated, high-throughput assay for the detection of SARS-CoV-2, influenza A (Flu A) and influenza B (Flu B) in one single assay.1

Assay box in lab background




    The Performance & Flexibility you Need

    Accurate and fully automated testing is critical in the fight against the threat of SARS-CoV-2. This is key to quickly identifying who’s infected and subsequently helping alleviate the spread of this virus. The assay is used for the qualitative detection and differentiation of SARS-CoV-2, influenza A virus and influenza B virus from individuals suspected of respiratory viral infection consistent with COVID-19.1

    The Power to Choose & Potential to Grow

    Leverage the flexibility and scalability of the Panther® System.


    Meet any urgent need for high-throughput and fully-automated testing, delivering more than 1000 test results in 24 hours.*,2


    Detect and differentiate SARS-CoV-2 and influenzas A and B during respiratory season to guide patient management.1


    The assays can be run alongside current infectious disease, women’s health and virology assays, enabling laboratories to unlock the free capacity on their existing Panther Systems.

    Simplify & Scale the Future of Diagnostics

      The Aptima SARS-CoV-2 /Flu Assay is part of the Hologic Molecular Scalable Solution, a portfolio combining a broad, high performing assay menu with high throughput automation. Designed to flexibly scale to meet your needs, from a single patient result to population level screening.

    Technician walking through Panther systems in a lab setting

    Excellent Clinical Performance

    Evaluated in comparison to the Aptima SARS-CoV-2 Assay and the Panther Fusion Flu A/B/RSV assay, using a panel of remnant clinical nasopharyngeal specimens collected from patients with signs and symptoms of respiratory infection.

    96.1% Positive agreement

    99.6% Negative agreement SARS-CoV-21

    100% Positive agreement

    99.2% Negative agreement Influenza A1

    100% Positive agreement

    100% Negative agreement Influenza B1

    Challenges Facing Laboratories

    The COVID-19 pandemic put unprecedented pressures on laboratories across the globe.

    • Huge sample demand, underscoring the need for high-throughput molecular automation3
    • Requirement to deliver rapid results to patients and clinicians3
    • Uncertainty around the future for SARS-CoV-2 and other respiratory viruses4,5

    Hologic was in the right place at the right time to make a profound impact on human health. Learn more about our collaboration and journey with labs during the pandemic and beyond.

    Lab technician pushing tray of vials into medical system

    Applicable Specimen Types

    Applicable specimen types include nasopharyngeal and nasal swab specimens collected in UTM/VTM, saline, Liquid Amies or Aptima Specimen Transport Medium.1

    Evidence. Insight. Collaboration.

    Our education portal improves patient care through excellence in education, communication of clinical and scientific evidence, and partnerships with the healthcare community.

      *The number of actual test results per day may vary based on individual lab practices and workflows
      1. Aptima SARS-CoV-2/Flu Assay [package insert]. AW-22365-001 Rev. 004. San Diego, CA: Hologic, Inc.; 2023
      2. Panther/Panther Fusion System Operator´s Manual. AW-26055-001 Rev 001, San Diego, CA: Hologic Inc.; 2022.
      3. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol. 2021 Mar;19(3):171-183. doi: 10.1038/s41579-020-00461-z. Epub 2020 Oct 14. PMID: 33057203; PMCID: PMC7556561.
      4. Messacar K, Baker RE, Park SW, Nguyen-Tran H, Cataldi JR, Grenfell B. Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption. Lancet. 2022 Jul 14:S0140-6736(22)01277-6. doi: 10.1016/S0140-6736(22)01277-6. Epub ahead of print. Erratum in: Lancet. 2022 Jul 18;: PMID: 35843260; PMCID: PMC9282759.
      5. Baker RE, Park SW, Yang W, et al. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30547-30553. doi: 10.1073/pnas.2013182117. Epub 2020 Nov 9. PMID: 33168723; PMCID: PMC7720203.



      Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium.

      Notified Body number wherever applicable

      EC Representative Information wherever applicable